Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Up 9% Following Analyst Upgrade

Tandem Diabetes Care, Inc. (NASDAQ:TNDM)’s share price rose 9% on Monday after Lake Street Capital upgraded the stock from a hold rating to a buy rating. Lake Street Capital now has a $50.00 price target on the stock. Tandem Diabetes Care traded as high as $27.92 and last traded at $26.7820. Approximately 857,729 shares traded hands during mid-day trading, a decline of 45% from the average daily volume of 1,572,325 shares. The stock had previously closed at $24.57.

Several other analysts also recently issued reports on TNDM. TD Cowen started coverage on Tandem Diabetes Care in a research note on Tuesday, January 27th. They issued a “buy” rating and a $25.00 price target on the stock. Truist Financial set a $24.00 price objective on Tandem Diabetes Care and gave the stock a “hold” rating in a report on Thursday, December 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Tandem Diabetes Care in a research note on Wednesday, January 21st. Robert W. Baird set a $30.00 price target on Tandem Diabetes Care and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. Finally, UBS Group reaffirmed a “neutral” rating and set a $22.00 price target (up from $17.00) on shares of Tandem Diabetes Care in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Tandem Diabetes Care has an average rating of “Hold” and an average target price of $28.00.

Tandem Diabetes Care News Roundup

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Q4 execution — Company beat on revenue and posted better-than-expected EPS in the latest quarter, with management signaling solid operational execution that underpins today’s buying interest. Article Title
• Positive Sentiment: Analyst action — Truist reaffirmed a “hold” but raised its price target (from $24 to $27), a modest vote of confidence that likely supported upside after the earnings beat. Article Title
• Neutral Sentiment: Company filing — Tandem confirmed it intends to privately place $200M aggregate principal of convertible senior notes due 2032 to qualified institutional buyers; terms/convertibility details and timing are subject to market conditions. This is a factual disclosure that creates financing optionality but also potential dilution risk. Article Title
• Neutral Sentiment: Earnings-call takeaways — Management signaled a strategic shift (pay-as-you-go transition and other initiatives) that investors should monitor for margin and cash-flow implications; these are longer-term operational items rather than immediate catalysts. Article Title
• Negative Sentiment: Convertible-debt market reaction — Media coverage and traders reacted negatively to the $200M convertible offering announcement, citing dilution and financing concerns; several wires reported immediate selling pressure after the news. Article Title
• Negative Sentiment: Institutional selling & flows — Reports that the Brown Capital Management Small Company Fund sold its TNDM position likely amplified volatility and contributed to near-term selling pressure. Article Title
• Negative Sentiment: Mixed analyst/target moves — Other published price-target notes are below current trading levels (e.g., a $22 target reported by some outlets), reinforcing mixed expectations and adding to intraday selling dynamics. Article Title

Institutional Trading of Tandem Diabetes Care

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Tandem Diabetes Care by 3.9% in the fourth quarter. Vanguard Group Inc. now owns 7,341,356 shares of the medical device company’s stock valued at $161,363,000 after acquiring an additional 278,042 shares during the last quarter. ArrowMark Colorado Holdings LLC raised its holdings in shares of Tandem Diabetes Care by 36.7% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 3,691,198 shares of the medical device company’s stock valued at $44,811,000 after purchasing an additional 991,649 shares during the period. Hood River Capital Management LLC lifted its stake in Tandem Diabetes Care by 10.9% in the 2nd quarter. Hood River Capital Management LLC now owns 2,564,978 shares of the medical device company’s stock valued at $47,811,000 after purchasing an additional 252,934 shares during the last quarter. Paradice Investment Management LLC grew its holdings in Tandem Diabetes Care by 24.3% during the third quarter. Paradice Investment Management LLC now owns 2,196,468 shares of the medical device company’s stock worth $26,665,000 after purchasing an additional 429,289 shares during the period. Finally, Jennison Associates LLC increased its position in Tandem Diabetes Care by 42.3% during the fourth quarter. Jennison Associates LLC now owns 2,021,376 shares of the medical device company’s stock worth $44,430,000 after buying an additional 601,260 shares during the last quarter.

Tandem Diabetes Care Trading Up 15.0%

The company has a debt-to-equity ratio of 2.00, a current ratio of 2.55 and a quick ratio of 2.02. The business has a 50-day simple moving average of $21.04 and a two-hundred day simple moving average of $17.16. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of -9.21 and a beta of 1.68.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its earnings results on Thursday, February 19th. The medical device company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.04. The company had revenue of $290.38 million during the quarter, compared to the consensus estimate of $277.14 million. Tandem Diabetes Care had a negative return on equity of 68.23% and a negative net margin of 20.17%.The firm’s revenue for the quarter was up 15.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.01 EPS. Equities analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.